Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.

ABSTRACT:

Importance

The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/or drug supplies for patients.

Objective

To assess the virologic efficacy of casirivimab and imdevimab across different IV and SC doses compared with placebo.

Design, setting, and participants

This phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study included outpatients with SARS-CoV-2 infection at 47 sites across the United States. Participants could be symptomatic or asymptomatic; symptomatic patients with risk factors for severe COVI

SUBMITTER: Portal-Celhay C 

PROVIDER: S-EPMC9379747 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature